Summary of WYETH - Yahoo! Finance

Material Modification to Rights of Security Holders, Financial Statements and Exhibits

Item 3.03 Material Modification to Rights of Security Holders.

On October 16, 2009, Pfizer Inc. ("Pfizer") commenced a consent solicitation to seek consent from the holders of Wyeth's 6.700% Notes due 2011 (CUSIP No. 026609AM); 6.700% Notes due 2011 (CUSIP No. 026609AJ); 5.250% Notes due 2013 (CUSIP No. 983024AA); 5.500% Notes due 2014 (CUSIP No. 983024AE); 5.500% Notes due 2016 (CUSIP No. 983024AJ); 5.450% Notes due 2017 (CUSIP No. 983024AM); 7.250% Notes due 2023 (CUSIP No. 026609AC); 6.450% Notes due 2024 (CUSIP No. 983024AF); 6.500% Notes due 2034 (CUSIP No. 983024AG); 6.000% Notes due 2036
(CUSIP No. 983024AL); and 5.950% Notes due 2037 (CUSIP No. 983024AN)
(collectively, the "Securities"), to amend certain provisions of the Indenture, dated April 10, 1992, by and among Wyeth, as successor to American Home Products Corporation and The Bank of New York Mellon ("Trustee"), as successor to Manufacturers Hanover Trust Company, as trustee, as amended (the "Indenture").

On October 30, 2009, Pfizer announced that it had received consent from at least a majority in aggregate principal amount of Securities outstanding (the "Required Consents"). As a result of Pfizer's receipt of the Required Consents, Wyeth entered into the Eighth Supplemental Indenture ("Eighth Supplemental Indenture"), dated as of October 30, 2009, among Wyeth, Pfizer and the Trustee. The Eighth Supplemental Indenture is attached as Exhibit 4.1 hereto and incorporated by reference herein. Pursuant to the Eighth Supplemental Indenture,
(i) Pfizer issued an unconditional and irrevocable guarantee (the "Pfizer Guarantee") of the prompt payment, when due, of any amount owed to the holders of the Securities and (ii) certain provisions of the Indenture related to (a) the consolidation or merger of Wyeth or the sale of all or substantially all of Wyeth's assets; (b) the limitation on Wyeth's incurrence of liens; (c) the limitation on sale and leaseback transactions by Wyeth; (d) Wyeth's obligation to publish certain notices in Luxembourg; (e) the cure period in connection with a default in the payment of interest with respect to the Securities; (f) the annual date prior to which Wyeth must deliver a compliance certificate to the Trustee; and (g) Wyeth's obligation pursuant to the Indenture to file certain SEC reports with the Trustee, were amended.